Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines

Leukemia

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Gieseler, F ^a,f   Glasmacher, A ^b   Kampfe D ^c   Wandt, H ^d   Nuessler, V ^e   Valsamas, S ^a   Kunze, J ^a   Wilms, K ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Department of Hematology Oncology   (Germany)

^d University Hospital   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Medizinische Poliklinik   (Germany)

Author keywords

Acute myeloid leukemia; Chemotherapy; Prognostic factor; Topoisomerases

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME ANTIBODY; ENZYME INHIBITOR; EPIPODOPHYLLOTOXIN; ETOPOSIDE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; CONFERENCE PAPER; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029802006     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Tewey KM, Rowe TC, Yang L, Halligen BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-468.
2. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 1989; 28: 6157-6160.
3. Bruno S, Del BC, Lassota P, Giaretti W, Darzynkiewicz Z. Inhibitors of proteases prevent endonucleolysis accompanying apoptotic death of HL-60 leukemic cells and normal thymocytes. Leukemia 1992; 6: 1113-1120.
4. Gieseler F, Boege F, Biersack H, Spohn B, Clark M, Wilms K. Nuclear topisomerase II activity changes during HL-60 cell differentiation: alterations of drug sensitivity and pH-dependency. Leuk Lymphoma 1991; 5: 273-279.
5. Gieseler F, Kempfe D, Glasmacher A, Clark M, Valsamas S, Kunze J. Differentiation-dependent topoisomerase-activities in human myeloid leukemia-cells and their sensitivities to cytostatic drugs. Recent Results Cancer Res 1995 (in press).
6. Francis GE, Tejedor MC, Berney JJ, Chresta CM, Delgado C, Patel P. Effects of DNA topoisomerase Il inhibitors on human bone marrow progenitor cells. Leukemia 1994; 8: 121-128.
7. Gromova I, Biersack H, Jensen S, Nielsen IS, Westergaard O, Andersen AH. Heterodimers consisting of topoisomerase II alpha and beta subunits are a natural constituent of the topoisomerase II population in HeLa cells. The Sixth Conference on DNA Topoisomerases in Therapy. 1995; 15.
8. Tan KB, Dorman TE, Falls KM et al. Topoisomerase IIα and topoisomerase IIβ genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 1992; 52: 231-234.
9. D'Incalci M. DNA-topoisomerase inhibitors. Curr Opin Oncol 1993; 5: 1023-1028.
10. Del Bino G, Li X, Traganos F, Darzynkiewicz Z. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by anti-tumor drugs. Leukemia 1994; 8: 281-288.
11. Stammler G, Sauerbrey A, Volm M. Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and RT-PCR. Cancer Lett 1994; 84: 141-147.
12. McKenna SL, West RR, Whittaker JA, Padua RA, Holmes JA. Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 1994; 8: 1498-1502.
13. Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26. Biochem Pharmacol 1994; 48: 1785-1795.
14. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Pathol 1995; 146: 1302-1380.
15. Sorensen M, Sehested M, Jensen PB. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase 1-directed drug topotecan. Br J Cancer 1995; 72: 399-404.
16. Sambrook J, Fritsch E, Maniatis T. Immunoprecipitation of the target protein. Molecular Cloning, 2nd edn. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1989, 18.44-18.46.
17. Page B, Page M, Noel C. A new fluorimetric assay for cytotoxicity measurements in vitro. Int J Oncol 1993; 3: 473-476.
18. De Vore R, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res 1992; 52: 2156-2161.
19. Gasser SM, Walter R, Dang Q, Cardenas ME. Topoisomerase II: its functions and phosphorylation. Antonie Van Leeuwenhoek 1992; 62: 15-24.
20. Boege F, Geiseler F, Kjeldsen E. Treatment of HL-60 cells with amsacrine or VP-16 induces rapid proteolsis-associated elimination of DNA-complexed topoisomerase II from the nuclei. Proc AACR 1994; 35: 362.
21. Stevnsner T, Bohr VA. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair. Carcinogenesis 1993; 14: 1841-1850.
22. Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis 1993; 14: 2341-2351.